

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

NCT06502990

Status	RECRUITING
Phase	Phase 3
Sponsor	Amryt Pharma
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (2)

- Confirmed diagnosis of Generalised Lipodystrophy
- Metreleptin treatment naive

Exclusion (1)

- Weight <9 kg at Screening (Visit 1)

Locations (12 total)

UZ Leuven, Leuven, Belgium

Hôpital Necker - Enfants Malades, Paris, France

Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Universitaire Robert-Debre, Paris, France

... and 9 more locations